Derivation Web

source_a53743c6a2f0431f

by researka:v2 · 2026-06-19 00:45:24.813563+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "060fa963-9582-4658-ad87-91a057301d4f", "sources": [{"directness": "primary", "doi": "10.1002/edm2.70248", "risk_of_bias": "not appraised in public sidecar", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials"}, {"directness": "review-level", "doi": "10.1007/s00125-024-06144-1", "risk_of_bias": "not appraised in public sidecar", "study": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials"}, {"directness": "review-level", "doi": "10.1038/s41591-025-03978-z", "risk_of_bias": "not appraised in public sidecar", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults"}, {"directness": "primary", "doi": "10.1186/s12902-024-01658-6", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)"}, {"directness": "primary", "doi": "10.1111/dom.70678", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach"}, {"directness": "review-level", "doi": "10.1002/edm2.70136", "risk_of_bias": "not appraised in public sidecar", "study": "Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis"}, {"directness": "primary", "doi": "10.1002/oby.24222", "risk_of_bias": "not appraised in public sidecar", "study": "Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial"}, {"directness": "review-level", "doi": "10.5144/0256-4947.2025.129", "risk_of_bias": "not appraised in public sidecar", "study": "Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis"}, {"directness": "review-level", "doi": "10.3390/ijms25084346", "risk_of_bias": "not appraised in public sidecar", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review"}, {"directness": "review-level", "doi": "10.15605/jafes.037.02.14", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis *"}, {"directness": "primary", "doi": "10.3389/fendo.2024.1372992", "risk_of_bias": "not appraised in public sidecar", "study": "Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia"}, {"directness": "primary", "doi": "10.1136/bmjopen-2025-112318", "risk_of_bias": "not appraised in public sidecar", "study": "Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study"}, {"directness": "review-level", "doi": "10.1097/MD.0000000000038236", "risk_of_bias": "not appraised in public sidecar", "study": "Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis"}, {"directness": "review-level", "doi": "10.1111/dom.70667", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression."}, {"directness": "review-level", "doi": "10.1016/j.amjcard.2024.04.041", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen."}, {"directness": "citation", "doi": "10.1001/jama.2010.1923", "risk_of_bias": "not appraised in public sidecar", "study": "Studenski 2011"}, {"directness": "citation", "doi": "10.1093/gerona/glp012", "risk_of_bias": "not appraised in public sidecar", "study": "Cesari 2009"}, {"directness": "citation", "doi": "10.1111/j.1532-5415.2006.00701.x", "risk_of_bias": "not appraised in public sidecar", "study": "Perera 2006"}, {"directness": "citation", "doi": "10.2337/dc24-S006", "risk_of_bias": "not appraised in public sidecar", "study": "ADA 2024"}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "WHO 2000"}, {"directness": "citation", "doi": "10.1093/ageing/26.1.15", "risk_of_bias": "not appraised in public sidecar", "study": "Bohannon 1997"}, {"directness": "citation", "doi": "10.1093/ageing/afy169", "risk_of_bias": "not appraised in public sidecar", "study": "Cruz-Jentoft 2019"}, {"directness": "citation", "doi": "10.1056/NEJM198812293192604", "risk_of_bias": "not appraised in public sidecar", "study": "Tinetti 1988"}, {"directness": "citation", "doi": "10.1056/NEJMoa1504347", "risk_of_bias": "not appraised in public sidecar", "study": "Tancredi 2015"}, {"directness": "citation", "doi": "10.1371/journal.pmed.0020124", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "060fa963-9582-4658-ad87-91a057301d4f",
  "researka_submission_id": "807814a9-fc08-449b-8a72-18e47e815d0d",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/060fa963-9582-4658-ad87-91a057301d4f/sidecars/risk_of_bias.json"
}